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Edited by Patrick SungThe apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1),
the main AP-endonuclease of the DNA base excision repair
pathway, is a key molecule of interest to researchers due to its
unsuspected roles in different nonrepair activities, such as: i)
adaptive cell response to genotoxic stress, ii) regulation of gene
expression, and iii) processing of microRNAs, which make it an
excellent drug target for cancer treatment. We and others
recently demonstrated that APE1 can be secreted in the
extracellular environment and that serum APE1 may represent
a novel prognostic biomarker in hepatocellular and non-small-
cell lung cancers. However, the mechanism by which APE1 is
released extracellularly was not described before. Here, using
three different approaches for exosomes isolation: commercial
kit, nickel-based isolation, and ultracentrifugation methods
and various mammalian cell lines, we elucidated the mecha-
nisms responsible for APE1 secretion. We demonstrated that
APE1 p37 and p33 forms are actively secreted through extra-
cellular vesicles (EVs), including exosomes from different
mammalian cell lines. We then observed that APE1 p33 form is
generated by proteasomal-mediated degradation and is enzy-
matically active in EVs. Finally, we revealed that the p33 form
of APE1 accumulates in EVs upon genotoxic treatment by
cisplatin and doxorubicin, compounds commonly found in
chemotherapy pharmacological treatments. Taken together,
these findings provide for the first time evidence that a func-
tional Base Excision Repair protein is delivered through exo-
somes in response to genotoxic stresses, shedding new light
into the complex noncanonical biological functions of APE1
and opening new intriguing perspectives on its role in cancer
biology.
The base excision repair (BER) pathway is responsible
for repairing DNA lesions caused by alkylation damage or
oxidative stress conditions due to endogenous or exoge-
nous sources, including chemotherapy treatments (1, 2).
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BY license (http://creativecommons.org/licenses/by/4.0/).(APE1) is the main endonuclease that participates in the
BER pathway and recognizes abasic sites on DNA and
RNA in human cells (3, 4). In DNA, abasic sites can be
generated by the action of glycosylases, such as OGG1,
which are responsible for the recognition of modified ba-
ses and the hydrolysis of the N-glycosidic bond between
the damaged base and the deoxyribose (5). Upon the ac-
tion of APE1, a nick on the DNA backbone is introduced
at the 5’ of the abasic site, generating an abasic dRP,
which is subsequently processed by the downstream BER
pathway enzymes, including Polβ, XRCC1, Polδ, and li-
gases (6). The generation of abasic sites in RNA is still a
matter of debate, but its occurrence has been associated
with profound biological consequences (7).
Besides its crucial role in the BER pathway, APE1 exerts
several nonrepair functions, which have been characterized in
the last 20 years (2, 8), such as: i) the redox regulation of
transcription factors; ii) the control of redox homeostasis; and
iii) the activity in metabolism and stability on coding and
noncoding RNAs (ncRNAs) (9).
The multifunctional activity of APE1 depends on a modular
structure characterized by three functional subregions: i) the
N-terminal region, including the first 33–35 unstructured
amino acidic residues, which is mainly involved in the stabi-
lization of protein–protein or protein–RNA interaction (10);
ii) the central region of the protein, comprising amino acid 35
to amino acid 127, which exerts the nonrepair activities based
on redox mechanisms; and iii) the C-terminal domain, which
entails the AP-endonuclease activity responsible for DNA
repair (11). Interestingly, the 33–35 unstructured domain can
be cleaved off by proteasomal-mediated mechanisms (12, 13),
representing a mechanism to modulate APE1 different
functions.
Biological evidence for the multifunctional activities of
APE1 is supported by omics data, obtained in APE1 knock-
down HeLa cells, showing significant variations in the
expression of hundreds of genes, associated with: i)
mitochondrial-mediated apoptosis; ii) dysregulation of the
intracellular redox state, and iii) generation of membraneJ. Biol. Chem. (2021) 296 100569 1
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APE1 endonuclease is secreted through exosomesruffling, as a consequence of a modification of the cytoskeleton
(10).
APE1 can act as a coactivator or as a corepressor of gene
transcription through redox-dependent (for this reason, APE1
is also called Ref-1, redox effector factor 1) and redox-
independent mechanisms (14). In the redox-based mecha-
nism, which involves cysteine residues susceptible to redox
regulation (14–16), APE1 promotes the activation of tran-
scription factors (such as NF-κB, AP1, HIF-1α, and STAT3)
involved in chemoresistance responses, by modulating their
redox state and promoting their activation upon different
stimuli (10, 17).
More intriguingly, and largely unexplored yet, is the un-
suspected role of APE1 in RNA metabolism, which plays a
significant impact on microRNAs (miRNAs) expression
(10, 18). We recently demonstrated that APE1 is involved in
controlling miRNAs stability and regulation, during oxidative
stress conditions, through the interaction with DROSHA (18).
An alteration of miRNAs expression profile was observed in
human osteosarcoma cells upon APE1 knock-down (19).
Analysis of promoters regulating a list of miRNAs affected by
APE1 downregulation and involved in cell growth, cell
signaling, and cancer development clearly showed the pres-
ence of putative binding sites for transcription factors, such as
NF-κB, p53, HIF-1α, AP1, and c-Myc, redox-regulated by
APE1. These observations suggested that APE1 could indi-
rectly regulate gene expression through miRNAs transcrip-
tional control of target genes (19). It is also emerging that the
different functions of APE1 are modulated by distinct inter-
actomes, which redirect the protein activities to different
substrates (20).
These findings provided the molecular basis for considering
APE1 as a prognostic factor in several tumors such as: ovarian,
hepatic, pulmonary, and neurologic cancers (8, 9, 21, 22), in
which the protein is often overexpressed in both the nuclear
and cytoplasmic compartments. For all these reasons, it can be
hypothesized that a dysregulation of APE1 expression may
contribute to tumor development and progression through
mechanisms independent from the canonical DNA repair
function (18). APE1 is also emerging as an important predic-
tive factor being associated with chemoresistance phenomena
due to its positive role in expression of cancer resistance genes,
such as MDR1 and others (23, 24).
Interestingly, APE1’s presence in the extracellular milieu is a
novel unsuspected biological aspect of the protein, yet poorly
characterized (25–27). The link between APE1 amount in sera
and tumor progression and chemoresistance was proved in a
previous study performed on non-small-cell lung cancer
(NSCLC) patients, in which the levels of serum APE1 (sAPE1)
resulted significantly more elevated than in healthy controls
and were associated with a worse progression-free survival
(28). Therefore, sAPE1 is actually considered as a novel
biomarker for the prognosis of NSCLC (28). Confirmatory
results, along these lines, were recently obtained by our labo-
ratory in a cohort of hepatocellular carcinoma (HCC) patients
(29), in which we found that sAPE1 levels correlated with poor
prognosis and were able to discriminate between cancer2 J. Biol. Chem. (2021) 296 100569patients and cirrhotic or healthy donors (29). The presence of
this protein in sera of patients is not solely restricted to cancer
diseases but also in inflammatory models, such as coronary
artery disease (30) and endotoxemia (31).
The biological function of secreted APE1 is still completely
unknown. An intriguing hypothesis considers that it might act
as a paracrine molecule in triggering cell-to-cell communica-
tion, important for the local tissue microenvironment in-
flammatory response (25–27, 29).
Also evidences on the mechanisms responsible for APE1
secretion are lacking, even though the importance of the
acetylation, occurring on specific lysine residues sited in the
first 33 N-terminal portion of the protein, has been highlighted
in cells treated with the histone deacetylase inhibitor trichos-
tatin A (TSA) (25). However, it seems reasonable that APE1
secretion might derive from extracellular vesicle formation via
endosomal sorting complex (ESCRT), due to the protein
lacking of a classic secretory signal peptide (28). This pathway
is responsible for the biogenesis and maturation of multi-
vesicular bodies (MVBs), composed of many intraluminal
vesicles (ILVs), which are released in the extracellular milieu as
exosomes. ILVs formation can occur through several mecha-
nisms, and information about the regulation of these processes
and the possible differences between the promoted cargo se-
lection is still missing (32).
In this work, by using different biochemical techniques and
several tumor and nontumor cell lines, it was demonstrated
that secreted APE1 is exosome-associated. We also found that
APE1 secretion is an active mechanism, exacerbated by gen-
otoxic treatments, and that the secreted protein is enzymati-
cally active. Altogether, these findings add new light in
understanding the complex biological roles of APE1 in
mammalian cells.Results
APE1 protein is secreted through exosomes in EVs from HCC
cancer cell line
Recent evidence obtained from human monocytes, upon
inflammatory challenges, indicated the presence of APE1 in
the extracellular milieu and possibly associated with EVs (26).
In our previous work, we found that APE1 may be released in
sera of HCC patients, with significantly higher levels in com-
parison to healthy donors (29). Thus, we evaluated whether
APE1 could be secreted through small EVs, e.g., exosomes,
using the JHH-6 HCC cell line.
First, we isolated EVs from JHH-6 serum-free media using
Exosome isolation kit (Invitrogen) and characterized the
quality of the preparations obtained, as indicated in Material
and Methods. JHH-6 cells were kept in culture for 24h under
serum starvation conditions and then EVs were isolated. Pu-
rified particles were analyzed by Dynamic Light Scattering
(DLS), using the NanoSight instrument, and nanoparticle
tracking analysis (NTA). Figure 1A shows a representative
distribution of vesicles with a mean concentration of 1.39e +
09 ± 0.00e + 00 particles/ml, with a mode of 149.5 nm and an
average of 237 nm, ranging from 50 to 550 nm of the main
Figure 1. EVs characterization and APE1 protein content analysis in JHH-6 cells: A, average size distribution curve determined by NTA of EVs derived
from JHH-6 conditioned medium. The average concentration of vesicles was plotted against their size. The mean mode sizes and standard deviations are
reported nearby the curve. B, western blotting analysis performed in JHH-6 WCE and EXE for APE1 detection (predicted molecular weight 37 kDa). APE1 p37
and p33 forms were observed in EXE. WCE were used as a positive APE1 control (lower panel). Golgi apparatus protein GM130 (apparent molecular weight
130 kDa) was assayed as exosome negative marker, Alix (apparent molecular weight 95 kDa) and Syntenin (apparent molecular weight 32 kDa) were
assayed as exosome positive markers. C, AlphaScreen assay titrating the recombinant rGST-APE1 protein using Glutathione Donor beads and Protein A/G
Acceptor beads in the presence of anti-APE1 antibody. The signal of the recombinant protein was detected in NBI-isolated vesicles upon a 95 C heating
step. The specific fluorescence counts, indicating a high signal to background ratio, were normalized to background after subtraction of the aspecific
binding when considered at two EV concentrations in the scatter plot.
APE1 endonuclease is secreted through exosomespopulations. The morphology of the recovered EVs, which
peaked at 150 nm in size, was assessed by Transmission
Electron Microscopy, confirming the presence of round-
shaped vesicles with a mean diameter around 80 nm (data
not shown). Then, we performed a protein analysis of exoso-
mal markers. Western blot analysis of EVs (EXE) confirmed
the presence of Syntenin and Alix proteins, luminal markers of
EVs from endosomal origin, in contrast to the Golgi apparatus
protein GM130, used as negative control (33–35) (Fig. 1B).
Therefore, this preliminary characterization confirmed that
EVs included exosomes.
Furthermore, we analyzed the presence of APE1 in EVs. As
shown in Figure 1B, EXE from JHH-6 cells confirmed the
presence of a specific band of 37 kDa (APE1 p37) corre-
sponding to the full-length APE1 protein, as well as a faint
band corresponding to the truncated form of APE1 at 33 kDa,
indicated as APE1 p33. Notably, by using an antibody specific
for the N-terminal region of APE1, we demonstrated that this
truncated form corresponded to the NΔ33 one (Fig. S1 anddata not shown), which loses the first 33 amino acid residues as
a consequence of proteolysis, as already described in previous
papers (29, 36, 37).
To quantify APE1 protein levels in EVs, we used an EV
isolation procedure recently published (38), i.e., nickel-based
isolation (NBI), allowing to minimize particle aggregation in
solution and suitable for combination with homogeneous as-
says (39). We applied NBI to the media of JHH-6 cells to
isolate EVs and then combined an amplified luminescence
proximity homogeneous assay (alpha). We designed the alpha
assay using purified and quantified recombinant Glutathione
S-transferase-APE1 (rGST-APE1WT) (Fig. S2). The alpha assay
was performed using Glutathione-Donor beads and Protein G-
Acceptor beads recognizing the anti-APE1 antibody. We
tested the detection of the recombinant protein by titrating the
purified rGST-APE1WT protein, protein lysates from JHH-
6 cells, and purified GST alone as further control (Fig. 1C). We
then exploited the recombinant protein as a reference sub-
strate in the alpha assay. In this setting, we sensitively andJ. Biol. Chem. (2021) 296 100569 3
Figure 2. APE1 is associated to exosomes isolated by ultracentrifugation: A, workflow of the processing of cell-conditioned medium by
ultracentrifugation-based technique. B, size distribution of sEV/exo crude pellet was performed by nanoparticle tracking analysis (NTA). Numbers on the
graph represent the mode (most often occurring dimension). Note that the main peak corresponds to a mode of 126 nm. C, Western blotting analysis of
APE1 in iodixanol gradient fractions; exosomes (60 μg) obtained by ultracentrifugation of CM (48 h) from JHH-6 cells were loaded at the bottom of iodixanol
gradient and subjected to ultracentrifugation for 19 h. An equal volume of each fraction was analyzed for APE1 and Alix expression. The molecular mass
(MW), expressed in kDa, is shown on the left side of the image. Horizontal black line in correspondence to 70 kDa indicates the cutting site carried out for
blotting the membrane respectively with Alix (high) and APE1 antibodies. Fraction densities were determined by refractometry. D, flow cytometry analysis
of Hela- Dendra2 (left dot plot) and Hela-APE1-Dendra2 (right dot plot) transfected cells. The Dendra2 positive cells were identified by plotting fluorescence
at 525/540 nm versus side scatter channel. The Dendra2 positive cells were determined comparing the mock-transfected HeLa cells negative for Dendra2
expression (data not shown). E, flow cytometry analysis of APE1-Dendra2 in exosomes. Exosomes isolated by ultracentrifugation from CM of cells described
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APE1 endonuclease is secreted through exosomesspecifically detected the rGST-APE1WT in the low nanomolar
range compared with GST alone (Fig. 1C). In Fig. 1C, 100 nM
of rGST-APE1WT represents the hook point (Fig. S3). Subse-
quently, we isolated vesicles from JHH-6 cells by NBI (38) and
applied the alpha assay using a range of 102–105 vesicles, as
determined by the Tunable Resistive Pulse Sensing (TRPS)
technology and qNANO instrument with an NP250 nanopore
(the applied stretch gave a size window of approximately
100–800 nm for the majority of vesicle subpopulations
recovered). We only detected specific signals using EVs
exposed to 90 C denaturation for 5 min before titrating them
(Fig. 1C), indicating that recombinant rGST-APE1 is enclosed
within vesicles. According to the standard curve, obtained
using the purified rGST-APE1, we calculated the remarkable
amount of 1.27 ng of protein every 103 EVs having a size range
between 100 and 700 nm, shown in Fig. S4, and a recovery in
the range of 109 vesicles/ml.
To definitively assess whether the association of APE1 to
EVs was ascribable to exosomes, we combined biochemical
and cytofluorometric approaches on EVs isolated using an
ultracentrifugation-based protocol (40) (Fig. 2A), which rep-
resents a gold standard procedure to isolate small vesicles
including exosomes. The crude pellet was first characterized
for size distribution by using the Nanosight technology. The
results showed the presence of a main population with a mode
of 127 nm and a mean value of 164, 4 nm in accordance with
the expected exosome size (Fig. 2B). In the biochemical
approach, we evaluated the co-occurrence of density and dis-
tribution of APE1 and the exosome specific marker, i.e., Alix,
on an iodixanol gradient. Thus, cell-conditioned medium was
subjected to ultracentrifugation and the resulting pellet was
loaded onto 10–40% iodixanol gradient and centrifuged. The
obtained fractions were then analyzed for APE1 and Alix
content by western blotting. Results indicated the effective
codistribution of APE1 and Alix in fractions with a density
comprised between 1.08 and 1.18 g/ml, corresponding to the
one specific for exosomes (39) (Fig. 2C). The mobility of APE1
and Alix proteins in SDS PAGE was altered by iodixanol’s
presence.
In the final cytofluorometric approach, we took advantage
from an engineered cell line expressing the fluorescent APE1-
Dendra2 construct available in the Lab (41). Cells were first
analyzed for APE1-Dendra2 and Dendra2 expression, which
showed similar fluorescence (Fig. 2D). Then, we evaluated, by a
direct cytofluorometric analysis, the presence of APE1-
Dendra2 in isolated exosomes. Results showed the presence
of a single fluorescent population (Fig. 2E lower panel), with a
minimal background noise on 520/40 channel, as observed
under PBS condition (Fig. 2E upper panel). Interestingly, in the
control exosomes secreted from cells expressing Dendra2,
similarly to PBS condition, only few events could be registered
(Fig. 2E middle panel), thus indicating the specific association
of APE1 with exosomes. A final ultrastructural analysis byin (D) were resuspended with same volume of PBS. The number of events re
analyzed to establish the amount of background noise. The dot plot columns on
micrographs of exosomes obtained from HeLa-Dendra2 cells (F) and HeLa APscanning electron microscopy confirmed that in both exosome
samples analyzed by FACS, intact round-shaped vesicles of
50–100 nm size were present (Fig. 2, F and G).
Overall, these data indicate that APE1 is present in EVs in
association with exosomes.
p37 and p33 APE1 forms are secreted in exosomes of different
mammalian cell lines
In order to test whether the secretion of APE1 through
exosomes is a common feature of different mammalian cell
lines, we performed EXE analysis in lymphocyte mouse
isogenic cell lines, i.e., the non-tumor CH12F3Δ/+/+ and
CH12F3Δ/Δ/Δ, expressing or not APE1 through genetic dele-
tion, respectively (42). The use of these isogenic cell lines was
also instrumental to further demonstrate the identity of the
APE1 band recognized by the antibodies used in our study.
Using these two cell lines, we found that APE1 was indeed
exclusively present in the exosomes obtained from the
CH12F3Δ/+/+ cells expressing APE1, with a significant pres-
ence of the p33 form (Fig. 3A). Moreover, these data suggested
that the release of APE1 in exosomes was not exclusively
limited to JHH-6 cells. Indeed, testing exosomes obtained
from: A549 lung tumor cell line, HCT116p53+/+ and
HCT116p53-/- colon carcinoma isogenic cell lines confirmed
the general nature of this phenomenon (Fig. 3A). Moreover, in
order to confirm that the secretion of APE1 is common in
vesicles from non-cancer cell lines, we used two mouse em-
bryonic fibroblast (MEF) cell lines expressing or not Nucleo-
phosmin 1 (NPM1) (43), a known APE1–protein interacting
partner (44). Data obtained (Fig. 3B) enforced the presence of
APE1 in exosomes as a general occurrence in all mammalian
cell lines tested. Interestingly, we observed that the amount of
the p37 and p33 protein forms was different between cell lines
tested. These data clearly demonstrated that both the p37 and
p33 forms of the APE1 protein may be released, to different
extents and ratios, in exosomes of mammalian cell lines of
different origin.
Based on our previous characterization of the p33 form in
cancer cells from hematopoietic origin, i.e., acute myeloid
leukemia (36), we tested the distribution of APE1 in EXE of
OCI-AML3 (expressing the mutated NPM1c+ protein) and
OCI-AML2 control cells (45). These two cell lines represent a
suitable model for this analysis, as OCI-AML2 cells show
normal subcellular expression of APE1 protein with a promi-
nent nuclear distribution and no significant trace of theAPE1
p33 form (36). Interestingly, the OCI-AML3 cell line harbors a
driver mutation of the NPM1 gene, called NPM1c+, which
causes APE1 cytoplasmic localization and consequent BER
impairment (36). In OCI-AML3 cells, the APE1 protein is
relocalized within the cytoplasm, where it undergoes proteo-
lytic degradation of the first 33 amino acids at the N-terminal
sequence (12) (Fig. 3C-left panel). When the APE1 p37 and
p33 protein content in EXE, obtained from OCI-AML2 andgistered in 60 μl is shown in the histogram column (left). PBS (60 μl) was
the left show forward and side scatter of the acquired exosomes. F, electron
E1-Dendra2 cells (G). Bars, 200 nm.
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Figure 3. APE1 EVs secretion in a panel of mammalian cell lines: A, western blotting analyses for APE1 detection carried out in EXE of JHH-6, A549,
HCT116P53+/+, HCT116p53-/-, CH13F3Δ/+/+, and CH12F3Δ/Δ/Δ cells. Both APE1 p37 and p33 forms have been detected. Alix was used as a loading control. WCE
were analyzed as a positive control of APE1 expression. The molecular mass (MW) expressed in kDa is shown on the left side of the image. B, western
blotting analyses for APE1 detection carried out in EXE of MEFNPM1+/+ and MEFNPM1-/- cells. Both APE1 p37 and p33 forms have been detected. Alix was used
as a loading control. WCE were analyzed as a positive control of APE1 expression and β-Tubulin (apparent molecular weight 52 kDa) was detected as
loading control. Western blotting analysis for NPM1 detection was carried out as a control for cells genotype. The molecular mass (MW) expressed in kDa is
shown on the left side of the image. C, western blotting analyses for APE1 detection in WCE and EXE derived from OCI-AML2 and OCI-AML3 cell lines. β-
Tubulin (apparent molecular weight 52 kDa) and Alix (apparent molecular weight 95 kDa) detection was carried out as loading controls. APE1 p37 and p33
are indicated by arrows. The molecular mass (MW) expressed in kDa is shown on the left side of the image. The percentages of exosomal APE1 p37 and p33
forms in OCI-AML2 and OCI-AML3 cell lines are indicated in the scatter plot on the right panel and in Fig. S5. Data are expressed as mean ± SD of three
independent replicas.
APE1 endonuclease is secreted through exosomesOCI-AML3 cells, was examined, we observed that either of
forms is released by both cell lines, as shown in Figure 3C
(middle panel). In particular, in the OCI-AML2 cells, the
amount of total secreted APE1 (comprising both the p37 and
p33 APE1 forms) was higher than that secreted by the OCI-
AML3 cells. Interestingly, the ratio between the p37 and p33
APE1 forms was comparable between EXE of both cell lines
(Fig. 3C right panel and Fig. S5). These experiments indicate
that while the OCI-AML2 cells, in contrast to the OCI-AML3
cells, do not show any p33 protein form in WCE, as previously
observed (36), the p33 form was present in the vesicle extracts
of both cell lines at comparable levels. These data could sug-
gest that the secretion efficiency of the APE1 p33 form by
OCI-AML2 is higher than that of the OCI-AML3. Alterna-
tively, this data could indicate that a common proteolytic6 J. Biol. Chem. (2021) 296 100569event, which is absent in the cytoplasm of the OCI-AML2
cells, may also occur in exosomes.
APE1 p33 form in exosomes is generated through
proteasomal-mediated degradation
Recent published data from our lab clearly demonstrated
that the cleavage of APE1 N-terminal region, giving rise to the
p33 form of the protein, is, at least in part, caused by cyto-
plasmic proteasomal complex activity (12). In order to evaluate
whether the proteasomal pathway can be also involved in the
accumulation of the p33 form in exosomes, we blocked the
proteasome-mediated degradation with MG-132 inhibitor (46)
in JHH-6 cells. Figure 4A and Fig. S6 show a significant
reduction of the p33 form only upon MG-132 treatment,
demonstrating that the APE1 truncated form, accumulated in
Figure 4. APE1 proteolytic activity characterization in exosomes: A, western blotting analyses for APE1 p37 and p33 detection in EVs derived from JHH-6
MG-132 treated cells and the respective untreated CTR cells (left panel). Alix (apparent molecular weight 95 kDa) was used as loading control. The per-
centage of exosomal APE1 p37 and p33 forms in both CTR and MG-132 JHH-6 cells has been obtained by densitometry analysis, and it is indicated in the
scatter plot (middle panel) and in Fig. S6. Western blotting analysis for IκB-α (apparent molecular weight 38 kDa) detection was performed in CTR and MG-
132 treated JHH-6 WCE as a confirmation of proteases inhibition. The molecular mass (MW), expressed in kDa, is shown on the left side of the image. Data
are expressed as mean ± SD of three independent replicas. B, EVs possess proteases able to cleave rGST-APE1 protein. In vitro proteolytic activity exerted by
EXE (0.1 μg) upon rGST-APE1WT (0.2 μg) (apparent molecular weight 65 kDa). The reactions were performed at 37 C for the indicated times and the
substrates (A) and the products (AA) of reactions have been detected by Western blotting using APE1 antibody (left panel). rGST (0.2 μg) (apparent
molecular weight 29 kDa) indicated as () has been detected by western blotting using GST antibody. C, graph illustrating the comparison of EXE cleavage
activity upon rGST-APE1WT and rGST-APE1K4pleA. Data are expressed as mean ± SD of three independent technical replicas. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001.
APE1 endonuclease is secreted through exosomesthe exosomes, is substantially contributed by an intracellular
proteasomal activity. The efficacy of MG-132 treatment was
proved by evaluating the accumulation of IκB-α (47) in WCE,
as shown in Figure 4A, right panel.
Proteasomal components can be actively secreted in exo-
somes (48–50). We therefore tested whether exosomes could
contribute to APE1 N-terminal cleavage. For this purpose,
JHH-6 EXE was tested for its proteolytic activity using rGST-
APE1WT protein, as a substrate, in kinetics experiments. The
reactions were carried out for different times at 37 C. rGST
was used as an additional control of gel migration. Upon
reaction, the samples were denatured and separated on
SDS-PAGE. As shown in Figure 4B, JHH-6 EXE showed a
considerable time-dependent cleavage activity on rGST-
APE1WT protein, as demonstrated by western blot analysis
with an antibody specific for APE1 protein (Fig. 4B). Moreover,
analysis of the blot with an antibody specific for the GST
protein (Fig. S7) showed that exosomes’ proteolytic activity
was able to remove the GST tag from the rGST-APE1WT
fusion protein used as a substrate in these assays, considering
that the obtained products showed the expected molecularweight of the p37 form. In order to demonstrate the occur-
rence of cleavage at the N-terminal region of APE1, we used a
purified recombinant APE1 mutant (Fig. S2) bearing four Lys
(K27, 31,32, 35) substituted with Ala to abolish the sites
essential for APE1 proteasomal cleavage, as previously
demonstrated (12). Figure 4C, data not shown, and Fig. S7
clearly show that Lys to Ala substitution significantly
hampered the proteolytic activity by exosomes, demonstrating
that the observed activity occurs at the level of the region
31–35 of APE1, as previously demonstrated within cells. These
data indicate that APE1 cleavage involves the 33N-terminal
region of the protein and implies a role of the proteasome in
the cleavage step.
APE1 protein from exosomes extracts is enzymatically active
We then tested whether exosomal-APE1 was enzymatically
active on different kind of DNA substrates (51) bearing an
abasic deoxyribonucleotide in dsDNA mimicked by a tetra-
hydrofuran residue (ds_dF:dC), an abasic ribonucleotide
embedded in DNA (ds_rF:dC), and an r8oxoG embedded in
DNA (ds_r80x0G:dC), as depicted in Figure 5A. For thisJ. Biol. Chem. (2021) 296 100569 7
Figure 5. APE1 in exosomes is enzymatically active: A, schematic representation of dsDNA 25-mer substrates generated by annealing of ss_dC com-
plementary oligonucleotide (5’-GTTCAGGCCTAACACTACCGGATCC-3’) with IRDye fluorophore labelled ssDNA oligonucleotide (5’-GGATCCGGTAGTGT-
TAGGCCTGAAC-3’), where the G in the 13th position is modified in deoxy-tetrahydrofuran (dF) (light purple) or ribo-tetrahydrofuran (rF) (light blue) or
oxidized ribo-guanosine (r8oxoG) (pink). The 50 and 30 ends of each DNA strand are indicated. B, JHH-6 EXE-containing APE1 possesses endonucleolytic
activity on the canonical abasic dsDNA substrate. Representative denaturing polyacrylamide gel of EXE incision on ds_dF:dC oligonucleotide. The quantity
of EXE used, expressed in ng, is shown on the top of the figure. The reaction was performed for 15 min. Data are the mean of three independent technical
replicas. C, representative denaturing polyacrylamide gel of EXE (250 ng) incision on ds_dF:dC oligonucleotide for 15 min following pretreatment of EXE at
different concentrations (μM) of APE1 inhibitor #3 for 15 min. Different concentrations of DMSO (%) were used as control. The mean cleavage activity
expressed in percentage is indicated below the panel. Data represent the mean of three independent technical replicas. D, JHH-6 EXE-containing APE1
possesses endonucleolytic activity on abasic ribonucleotides embedded in dsDNA. Representative denaturing polyacrylamide gel of EXE incision on
ds_rF:dC oligonucleotide. The quantity of EXE used, expressed in ng, is shown on the top of the figure. The reaction was performed for 15 min. ds_dF:dC
oligonucleotide was used as positive control. In parallel, representative denaturing polyacrylamide gel of EXE incision on ds_dF:dC oligonucleotide is shown
in the right panel. Data represent the mean of three independent technical replicas and the mean cleavage activity expressed in percentage is indicated
below panels. E, JHH-6 EXE-containing APE1 possesses a weak endo- and exo-nucleolytic activity on oxidized ribo- G embedded in dsDNA. Representative
denaturing polyacrylamide gel of EXE incision on ds_r8oxoG:dC oligonucleotide. The amount of EXE used, expressed in ng, is shown on the top of the
figure. The EXE-containing APE1 activity was compared with the recombinant APE1 (rAPE1) activity on the same substrate at the indicated dose. The
reaction was performed for 30 min. The mean cleavage activity expressed in percentage is indicated below the panel. Data represent the mean of three
independent technical replicas.
APE1 endonuclease is secreted through exosomespurpose, we used increasing amount of EXE to test the APE1
endonuclease activity. First of all, we checked exosomal APE1
activity on canonical ds_dF:dC (Fig. 5B) by using classical
endonuclease assay (51). Results demonstrated that APE1 from
EXE was competent to process the canonical substrate
ds_dF:dC in a dose-dependent manner (Fig. 5B). Then, in
order to demonstrate whether the enzymatic activity of EXE
was exclusively ascribed to APE1, an endonuclease assay was
performed after treating EXE with different doses of com-
pound #3, a specific inhibitor of APE1 endonuclease activity
(44, 52) (Fig. 5C). This experiment confirmed that APE1 ac-
tivity in the EXE is the only endonuclease activity on abasic8 J. Biol. Chem. (2021) 296 100569dsDNA present within exosomes. Next, we tested whether
APE1 was able to process an abasic ribonucleotide embedded
in dsDNA (ds_rF:dC), similarly to what we recently found for
nuclear APE1 (51). Enzymatic assays clearly showed that
exosomal APE1 was able to efficiently process this substrate,
showing an activity even higher than that of the one observed
for the ds_dF:dC (Fig. 5D). Then, we tested the EXE activity on
a noncanonical substrate through an NIR activity, resembled
by a dsDNA of the same sequence as above, but containing an
oxidized ribonucleotide embedded in dsDNA in the middle
(ds_r8oxoG:dC), as we recently showed (51). As positive
controls of the incision on this substrate, we used recombinant
Figure 6. Genotoxic stresses cause the modulation of APE1 p37 and p33 forms in EVs: A, cell viability analyses carried out in JHH-6 cell line treated for
24, 48, 72 h with the indicated doses of Doxorubicin, expressed in μM and the respective untreated cells indicated as CTR. Data are expressed as mean ± S.D
of two independent replicas. B, analysis of APE1 accumulation and study of p37 and p33 distributions in JHH-6 EXE after treatments with sublethal
concentration of Doxo at the indicated time points. JHH-6 cells were treated with 0.25 μM of Doxo for 24, 48, and 72 h. Media were collected and processed
for obtaining EXE. EXE derived from JHH-6 untreated cells was analyzed as control (CTR). APE1 p37 and APE1 p33 patterns were analyzed by western
blotting. Alix and β-Tubulin were detected as loading controls. Densitometry analysis was performed and the percentage of secreted APE1 p33 fraction was
plotted in the scatter plot on the right. Row data of the percentage of APE1 p37 and p33 fractions are shown in Fig. S9. Data are expressed as mean ± SD of
three independent replicas. C, cell viability analyses carried out in A549 cell line treated for 24, 48, 72 h with the indicated doses of CDDP and the respective
untreated cells indicated as CTR. Data are expressed as mean ± S.D of two independent replicas. D, analysis of APE1 accumulation and study of p37 and p33
distributions in A549 EXE after treatments with sublethal concentration of CDDP at the indicated time points. A549 cells were treated with 6.25 μM of CDDP
for 24, 48, and 72 h. Media were collected and processed for obtaining EXE. EXE derived from A549 untreated cells was analyzed as control (CTR). APE1 p37
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APE1 endonuclease is secreted through exosomesAPE1 (rAPE1), to have a simultaneous evaluation of the ex-
pected products, and also Escherichia coli rRNase HII, which
possesses a stronger 5’ endonuclease activity on this substrate
(53). Data obtained (Fig. 5E) showed that APE1 from EXE
displays a weak NIR activity, similarly to recombinant purified
protein, as we previously demonstrated (51). Overall, these
experiments proved that exosomal APE1 is able to fully exert
its enzymatic activities on different DNA substrates containing
both canonical abasic sites and noncanonical (r8oxoG)
substrates.
Secretion of APE1 p33 form is stimulated by doxorubicin
treatment in the JHH-6 cell line and by cisplatin treatment in
A549 cells
We then wanted to test whether genotoxic stress may affect
APE1 release through exosomes. Doxorubicin (Doxo) is an
intercalating agent used in the treatment of HCC (54, 55). To
evaluate whether APE1 release could be affected by genotoxic
damage, we analysed APE1 secretion upon Doxo treatment.
First, we determined the proper treatment conditions, repre-
sented by sublethal doses of drug, in order to correlate the
effect of the treatment on EVs APE1 content with the viability
of JHH-6 cells. As shown in Figure 6A, the treatment with
Doxo, at the dose of 0.25 μM, was considered ideal because of
exerting low toxicity upon 24 h of treatment and a toxicity of
50% after 48 and 72 h of treatment. Then, JHH-6 cells were
treated for 24, 48, 72 h with Doxo at the concentration of
0.25 μM and the exosomes were isolated, as indicated before.
In parallel, the analysis of WCE (Fig. S8) clearly demonstrated
that Doxo treatment affected neither the expression of APE1
nor that of the Alix proteins. Interestingly, when we compared
the expression of APE1 in exosomes, upon Doxo treatment, we
noticed that the accumulation of the p33 form was increased
with respect to control cells, as quantified in the scatter plot, in
particular after 24 and 48 h of treatment (Fig. 6B right panel
and Fig. S9).
In order to check if this trend was only related to a specific
effect of Doxo treatment on exosomes release of APE1 or
whether it was common to other genotoxic treatments, JHH-
6 cells were treated with Cisplatin (CDDP), a DNA-cross-
linking agent commonly used in the treatment of NSCLC
(56, 57). Similar results were obtained using CDDP (data not
shown), confirming that different genotoxic agents may pro-
mote the release of higher amounts of the APE1 p33 form
compared with the p37 one in JHH-6 cells.
In order to have a more comprehensive view and extend the
observation to other cancer cell lines, we repeated the exper-
iment of CDDP treatment in the A549 lung cancer cell line.
We chose the concentration of 6.25 μM, as shown in
Figure 6C, because CDDP treatment at this concentration
caused low toxicity at 24 h and a toxicity of about 50% upon 48
and 72 h of treatment, similarly to what we observed for
JHH-6 cells. Then, we performed exosomes isolation fromand p33 patterns were analyzed by western blotting. Alix was detected as loa
secreted APE1 p33 fraction was plotted in the scatter plot on the right. Row d
Data are expressed as mean ± SD of three independent replicas. *p < 0.05, *
10 J. Biol. Chem. (2021) 296 100569A549-conditioned media after 24, 48, 72 h of CDDP treatment,
and we analyzed the amount of the APE1 p33 and p37 forms in
WCE and EXE. Similarly to JHH-6 cells, no differences of the
two APE1 protein forms were observed in WCE from A549,
treated with CDDP, compared with untreated control cells
(Fig. S10). Interestingly, we observed an accumulation of APE1
p33 form in EXE, compared with the p37 form, upon CDDP
treatment of A549 cells (Figs. 6D and S11). Coomassie blue
staining was carried out for A549 EXE loading control
(Fig. S12).
Altogether, these findings corroborate the hypothesis
that chemotherapeutic drugs may induce an exosomal accu-
mulation of the APE1 p33 form compared with the p37 pro-
tein in different cancer cell lines, possibly suggesting the
existence of different functions absolved by the p33 and p37
forms in EVs.
Discussion
APE1 is a multifunctional protein that participates in DNA
repair and in the regulation of gene expression. We have
recently demonstrated its role in RNA processing, as a major
AP endonuclease on abasic RNA (18, 24, 51) and on abasic
ribonucleotides embedded in DNA (24, 51). Noteworthy, this
unexpected activity on RNA possibly plays an important role
in miRNAs processing, modulating gene expression under
genotoxic stress conditions (18). Interestingly, elevated levels
of APE1 protein in sera of different tumors, such as HCC and
NSCLC, have been described (28, 29) and extracellular APE1
contribution in promoting chemoresistance, by affecting cell
sensitivity to chemotherapy, was suggested (28, 58), allowing
to hypothesize that sAPE1 could be considered as a prognostic
and predictive biomarker in cancer. Whether sAPE1 could
exert its biological function in association with extracellular
vesicles was not fully addressed, yet. Indeed, APE1 was found
associated, under basal conditions to EVs in human monocytes
(26), but studies focusing on the constitutive vesicles associa-
tion of APE1 in tumor cells, as well as a biochemical charac-
terization of a secreted form, were completely lacking.
Our study was aimed at addressing this issue, and we
demonstrated that, using several mammalian cell lines and
different orthogonal assays, APE1 is secreted through EVs,
particularly exosomes, and is enzymatically active. EVs repre-
sent a heterogeneous population comprising vesicles of
different biogenesis, such as exosomes from the endosomes
and microvesicles from plasma membrane budding. These can
overlap in size and protein composition, thus rendering their
specific analysis very difficult (59). In order to clearly establish
the exosomal association of APE1 within the bulky vesicular
population, we analyzed the physical characteristics of the EVs
(e.g., size and/or density ranges) and positivity to protein
markers, as indicated (60). Through combined biochemical
and different technological approaches (flow cytometry and
electron microscopy), we assessed the specific expression ofding control. Densitometry analysis was performed and the percentage of
ata of the percentage of APE1 p37 and p33 fractions are shown in Fig. S11.
*p <0.01, ***p < 0.001, ****p < 0.0001.
APE1 endonuclease is secreted through exosomesAPE1 in small EVs presenting density (1.08–1.18 mg/ml) and
dimension (120 nm) typical of exosomes.
The biological function exerted by APE1 through exosomes
remains to be elucidated. A recent study suggested a role of
sAPE1 in HCC as a paracrine proinflammatory molecule,
modulating the inflammatory status in cancer microenviron-
ment (29) and in human monocytes (26). Several studies re-
ported a role for secreted APE1 in inducing an apoptotic
signaling in triple-negative breast cancer (TNBC) cells through
RAGE receptor binding (61), whereas same interaction
observed in monocytic cells triggered signaling cascade
involved in inflammatory response (26). We can hypothesize
similar biological functions for exosome-associated APE1. In
addition, our finding on the vesicular-enclosed topology of
APE1 suggests the existence of a novel RAGE-independent
mechanism, which deserves further studies actually ongoing
in our laboratory. The extracellular release of APE1, not only
through exosomes, but also as soluble protein, cannot be
excluded, at present. Moreover, it was observed that APE1
extracellular release could be mediated by acetylation occur-
ring on the N-terminal region of the protein (61), but no clear
evidence about either the extracellular APE1 biological func-
tion or the mechanism responsible for its release has been
elucidated, yet. Other evidence claims that extracellular APE1
can control TNF-α-induced inflammatory response, modu-
lating the activation status of TNFR receptor through its redox
activity (27). Additional data suggest that exogenous APE1 can
participate in the early phases of the inflammation process, by
inducing the activation of IL-8 and IL-6 gene expression
through NF-κB (27). All these observations, together with our
findings about the effects of genotoxic treatments on APE1
release, could suggest that APE1 may act as a novel unsus-
pected damage associated molecular pathway (DAMP) factor.
This may indicate a novel noncanonical APE1 function as a
paracrine molecule, possibly involved in the inflammatory
response in tumor microenvironment (62) and in tumor
growth.
The sorting of APE1 to exosomes opens a new perspective
on the molecular mechanisms involved in APE1 secretion,
unknown so far. The APE1 protein lacks the classical secretory
signal even if its secretion was already described in several
works (25, 31). Although the route followed by APE1 in ves-
icles association is unknown, we can speculate that APE1
could follow the exosome packaging regulated through various
signaling networks. In particular, the biogenesis of exosomes
does occur within endosomes, later developing toward MVBs,
whose maturation is mainly driven by an ESCRT-dependent
mechanism. In support of this, ESCRT proteins, which are
crucial for packing MVBs, were found within exosomes (63).
However, several studies reported evidence for an ESCRT-
independent biogenesis (64, 65) and a role for the sphingoli-
pid ceramide, highly enriched in exosome membranes (66).
This sphingolipid together with high cholesterol level and
other sphingolipids forms lipid rafts inside endosomal mem-
branes, which force the coalescence of small into larger
microdomains, ultimately inducing budding and formation of
ILVs, later secreted as exosomes. Additional biochemicalcharacterization, actually ongoing in our lab, will clarify the
route followed by APE1 in vesicles association and secretion.
Regarding the mechanism responsible for APE1 sorting
into the exosomes, we found that the APE1-exosome
secretion process is a general mechanism in mammalian
cells and that APE1 can be found either as single p37 protein
form or as p33/p37 forms within exosomes due, at least in
part, to proteosomal activity. However, at present, we cannot
exclude that proteolytic events acting on APE1-N-terminal
region could preferentially occur at intracellular level or
within EVs upon secretion. Recently, some works high-
lighted that EVs could contain different kind of proteases,
including component of the proteasome (48, 49), some of
which were exposed to the EVs membrane and contributing
to the remodeling of extracellular matrix promoting tumor
invasiveness and sustaining inflammation processes (48, 49).
We observed that APE1 can undergo proteolytic cleavage,
within cells (this paper and (12)) and exosomes and that this
activity increased under genotoxic stress conditions (not
shown), but additional work is needed along these lines to
clarify the relevance of this phenomenon regulating APE1
sorting and its function within exosomes. Moreover, a
possible relevance of additional posttranslational modifica-
tions in regulating these phenomena cannot be excluded, at
present. The enhanced release of exosome-APE1 p33 form
upon different genotoxic stresses, specifically Doxo and
CDDP treatments used in the present study, is in line with a
previous study showing an increased release of exosomes of
nuclear origin deriving from micronuclei instability after
genotoxic damage in cancer cells (67). It is conceivable that
these vesicles might be highly shuttled between cells within
tumor mass and deliver their content within target cells. This
process may fulfill the cancer cells requirement of high
amount of APE1 to counteract the DNA damage inferred by
drugs in a paracrine manner, suggesting that APE1 secretion
could represent a novel DAMP mechanism, which deserves
further in-depth study. Importantly, these data provide the
rationale to investigate APE1 p33 accumulation in exosomes
from a liquid biopsy to monitor patients subjected to gen-
otoxic drugs.
In conclusion, we here demonstrated that APE1 is highly
secreted through exosomes from cancer cells after genotoxic
stress in different functional forms and that it is endowed with
enzymatic activity, possibly representing a novel DAMP factor.
These data add new light in the complex biological functions
of APE1 that could play important roles in chemoresistance
processes and tumor development.Experimental procedures
Cell culture and treatments
JHH-6, an undifferentiated HCC cell line, was grown in
William’s medium E (Sigma-Aldrich, Milan, Italy), supple-
mented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin (Euroclone, Milan, Italy). A549, hu-
man epithelial lung cell line and mouse embryonic fibroblast
(MEF) expressing (MEF NPM1+/+) or not NPM1 (MEFJ. Biol. Chem. (2021) 296 100569 11
APE1 endonuclease is secreted through exosomesNPM1−/−) (43) were grown in RPMI 1640 supplemented with
10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml
streptomycin (Euroclone). HCT116 p53+/+ and HCT116 p53−/−,
human epithelial colon cancer cell lines, were grown in Dul-
becco’s Modified medium (DMEM) supplemented with 10%
FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml
streptomycin (Euroclone). Acute myeloid leukemia cell lines
OCI-AML2, and OCI-AML3, the last one characterized by
having a mutation on the third helix of the C-terminal domain
(h3 mutA and H3 mutE) of NPM1 protein (36, 68), were
grown in α-MEM with ribonucleosides, 20% FBS, 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin
(Euroclone). CH12F3Δ/+/+, murine B cell line, biallelic for ape1
gene, and CH12F3Δ/Δ/Δ murine B cell line, allelic null for ape1,
were grown in RPMI 1640 medium supplemented with 10%
FBS, nonessential amino acids (Thermo Fisher Scientific,
Waltham, MA, United States), 1 mM sodium pyruvate, 50 μM
β-mercaptoethanol, 25 mM HEPES, 2 mM L-glutamine, 100
U/ml penicillin, 100 μg/ml streptomycin (Euroclone). HeLa,
human adenocarcinoma cells, were previously engineered for
APE1-Dendra2 and Dendra2 (41), and were grown in DMEM
high glucose (DMEM) supplemented with 10% FBS, 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin
(Euroclone). Cells were free from mycoplasma contamination.
The test was carried out using N-GARDE Mycoplasma PCR
Reagent (Euroclone).
Viability assay
JHH-6 or A549 was seeded at the density of 4*103 cells in
96-well plates. The day after seeding, cells were treated for 24,
48, and 72 h with the following genotoxic agents: Doxorubicin
hydrochloride (Sigma Aldrich), dissolved in UltraPure DNase/
RNase-Free Distilled Water (Invitrogen, Thermo Fisher Sci-
entific) or with cis-Diammineplatinum (II) dichloride (CDDP)
(Sigma Aldrich), dissolved in dimethylformamide (DMF), at
the indicated concentrations. The cellular viability was assayed
by using CellTiter 96 AQueous One Solution Cell Proliferation
Assay (Promega, Milan, Italy). Absorbance at 490 nm, indic-
ative of cellular metabolic activity, was measured with EnSpire
2300 Multilabel reader, (PerkinElmer, Waltham, MA, United
States). Each treatment was performed in two biological rep-
licates, and for each experiment a technical quadruplicate was
performed. Each absorbance value registered was standardized
with the absorbance value obtained from wells containing only
medium.
Exosomes isolation
Exosomes were isolated from medium supplemented with
10% FBS exosome-depleted (Thermo Fisher Scientific), 100 U/
ml penicillin, 100 μg/ml streptomycin (Euroclone), using Total
Exosome Isolation kit (Thermo Fisher Scientific), according to
the manufacturer’s instructions. Polydisperse EVs in the range
of 80–800 nm were obtained by NBI (38). Briefly, nickel-
charged beads were added to the media to capture EVs dur-
ing 30 min incubation at room temperature in shaking, then
EVs from recovered beads were eluted using a pH 7.4 elution12 J. Biol. Chem. (2021) 296 100569buffer containing EDTA and sodium citrate as chelating
agents.
Exosomes were also obtained by ultracentrifugation-based
method (40). Briefly, cell culture conditioned medium
(24–48 h) was subjected to serial centrifugation steps at 4 C.
The first one was at 700 x g for 10 min. The collected super-
natant was subjected to 2,000 x g for 20 min to remove protein
aggregates, and super was syringe-filtered (0.2 micron). Sam-
ples were then centrifuged at 15,000 x g for 20 min. Smaller
vesicles containing exosomes were isolated by high-speed ul-
tracentrifugation (100,000 x g for 3 h). Pellet was washed with
PBS without resuspension at 100,000 x g for 3 h.
Optiprep gradient centrifugation
We carried out a discontinuous iodixanol gradient floatation
as described in (69). Briefly, solutions of 40, 30, 10% iodixanol
were made by mixing appropriate amounts of a homogeniza-
tion buffer (0.25 M sucrose, 1 mM EDTA, 10 mM Tris-HCl
pH 7.4) and an iodixanol working solution (0.25 M sucrose,
6 mM EDTA, 60 mM Tris pH 7.4 plus stock solution of
Optiprep 60% (w/v), (Axis-Shield PoC, Norway). Exosomes
isolated with the ultracentrifugation-based method were
resuspended in PBS (260 μl) and added to 1 ml of 60% Opti-
prep and placed at the bottom of a polyallomer tube. The
gradient was formed by layering 0.5 ml of 40%, 0.5 ml of 30%,
1.8 ml of 10% solutions on top of each other and centrifuged
for 17 h at 192,000 × g in a SW60 rotor (Beckman Coulter,
Cassina de’ Pecchi, MI, Italy). Thirteen fractions (330 μl) were
collected from the top of the tube. The refractive index of each
fraction was assessed with a refractometer (Carl Zeiss, Ober-
kochen, Germany), and the relative density was calculated
using the linear relationship between the refractive index and
the density (70).
Exosome quantification and characterization
Exosomes range size analysis and quantification were
assayed by performing the nanoparticle tracking analysis
(NTA) with the Nano-Sight instrument, version NTA 3.2 Dev
Build 3.2.16, and for samples obtained by ultracentrifugation
with the Nano-Sight NS300 (Malvern, Worcestershire, UK).
EVs isolated by NBI were characterized by TRPS technology,
using qNANO instrument (IZON Science, Oxford, United
Kingdom) and NP250 nanopores. Stretch conditions and
quality of acquisitions were assessed based on CPC200 cali-
bration beads (IZON Science).
Amplified luminescent proximity homogeneous assay (alpha)
Glutathione-Donor beads (PerkinElmer, #6765300) and
Protein G-Acceptor beads (PerkinElmer, #AL102 C) were used
in saturation binding experiments to detect and quantify the
secreted, recombinant APE1 protein. Briefly, a mix of Donor
and Acceptor beads, at final concentration of 10 mg/ml each,
was added to 3 nM of APE1 antibody (13B8E5C2, Novus,
Colorado, USA) preincubated with increasing concentration of
rGST-APE1WT or GST to reach hooking point (38). In case of
EV experiments, aliquots of vesicles were denatured or not at
APE1 endonuclease is secreted through exosomes90 C for 5 min and equilibrated at RT before adding the alpha
mix of beads plus antibody (40). All the reactions were per-
formed in 20 μl as final volume in 384-Optiplates (Perki-
nElmer) and incubated for 1 h at RT before acquiring the
results with an Enspire Plate Reader (PerkinElmer). Curves
were analyzed by GraphPad Prism software v.5.
Whole-cell extracts preparation (WCE)
Cells were harvested, centrifuged at 1,200 rpm for 3 min,
washed with PBS, and resuspended with lysis buffer (50 mM
Tris HCl pH 7.5, 150 mM NaCl, 1 mM EDTA pH 8.0, 1%
Triton X-100) supplemented with 1 mM protease inhibitor
cocktail (Sigma), 0.5 mM phenylmethylsulfonyl fluoride
(PMSF). After 20 min of incubation on ice, the lysate was
centrifuged at 13,000 rpm to remove debris, and the whole-cell
extract (WCE) was collected and kept at –80 C.
Exosome extracts preparation (EXE)
Once the EVs were obtained, laemmli sample buffer (2%
SDS, 10% Glycerol, 0.5 M Tris-HCl pH 6.8, 3.5% β-mercap-
toethanol, bromophenol blue) was added to shatter the vesicles
and to denature their protein content. The samples were later
boiled for 5 min at 95 C and kept on ice until use.
Western blot analysis
Protein extracts were suitably quantified with Bradford so-
lution (Biorad, California, USA), according to the manufac-
turer’s instructions, loaded in 10% gel (SureCast Acrylamide
Solution (40%), Invitrogen), and transferred to nitrocellulose
membrane (Amersham, Little Chalfont, UK). Western blot
analyses were executed using the listed antibodies: anti-APE1
(13B8E5C2, Novus), anti-APE1 (N-terminus aa 1–14)
(NB100–897, Novus), anti-β-Tubulin (T0198, Sigma-Aldrich),
anti-Alix (1A12) (SC-53540, Santa Cruz, Texas, USA), anti-
GM130 (B-10) (SC-55591, Santa Cruz), anti-Syntenin
(EPR8102) (ab133267, Abcam), and anti-GST (ab19256,
Abcam). After incubation with primary antibodies, membranes
were washed three times with PBS 0.1% Tween-20, (Sigma
Aldrich), incubated for 1 h at room temperature with the
appropriate IRDye800/IRDye600 labeled secondary antibodies
(diluted to 1:2000). The acquisition of the images and the
quantifications analyses were achieved using Odyssey CLx
Infrared Imaging system (LI-COR GmbH, Germany).
FACS analysis of APE1-Dendra2
HeLa cell lines stably transfected with APE1-Dendra2 and
Dendra2 constructs (41) were cultured for 48 h with medium
supplemented with 10% FBS, exosome-depleted (Thermo
Fisher Scientific). Exosomes were obtained with ultracentri-
fugation method. The presence of fluorescent events in exo-
somal pellet was assessed by flow cytometry analysis as
reported (71) with minor modifications. Isolated exosomes
were resuspended with PBS (200 μl), then analyzed and
counted with CytoFLEX LX flow cytometer (Beckman
Coulter). The analysis was performed by plotting fluorescence
at 525/540 nm (FL1) versus log scale side scatter to determinethe fluorescence threshold value able to exclude the back-
ground noise. The instrument, calibrated to delivery sample
for absolute cell counts without using beads, was set at stop-
ping gate of 60 μl and fluorescence events in 595/540 nm
channel were recorded. To ensure the instrument resolution
and reliability, commercially available size standard fluorescent
beads (green fluorescent 505/515 flow cytometry submicron
particle size reference kit (Life Technologies)) were used.
Electron microscopy
Exosomes isolated by ultracentrifugation were analyzed by
scanning electron microscopy (SEM). Briefly, exosomes were
left to adhere on polylysine-treated round glass coverslips
(Ø10 mm) at room temperature. Then samples were fixed with
2.5% glutaraldehyde in 0.1 M Na-cacodylate buffer for 30 min
and post-fixed with 1% OsO4 in 0.1 M sodium cacodylate
buffer for 1 h. After fixation, samples were dehydrated through
a graded series of ethanol solutions (from 30 % to 100%). After
dehydratation, absolute ethanol was gradually substituted by a
1:1 solution of hexamethyldisilazane (HMDS)/absolute ethanol
and then by pure HMDS (72). Dried samples were mounted on
stubs, coated with 10 nm gold, and analyzed in a GeminiSEM
450 (Carl Zeiss).
Coomassie brilliant blue staining
Coomassie staining (0.05% Coomassie brilliant blue, 5%
acetic acid, 50% methanol) was carried out for 15 min, then the
10% polyacrylamide gels were incubated for 30 min in
destaining solution (25% methanol, 7% acetic acid). The
acquisition of the image was achieved using Odyssey CLx
Infrared Imaging system (LI-COR GmbH, Germany).
Recombinant proteins
Expression of human recombinant APE1 (rAPE1) was
produced as explained in (73–75).
E. coli RNase HII and bovine pancreas RNase A were pur-
chased from New England BioLabs Inc (Milan, Italy) and from
Sigma (Milan, Italy), respectively.
Proteolytic activity in exosomes
Extracellular vesicles were disrupted with 0.1% of PBS-
Triton X-100 (Sigma Aldrich) and their protein content was
later quantified with Bradford solution (Biorad). Different
concentrations of EVs proteins (0.1, 0.5, 1 μg) were incubated
with 200 ng of rGST-APE1WT, rGST-APE1K4pleA proteins, and
the reactions were performed at 37 C for 4 h. The reactions
were stopped adding Laemmli sample buffer. Samples were
later boiled for 5 min at 95 C. Each sample was loaded into
10% polyacrylamide gel, SDS PAGE was carried out, and finally
western blot was executed.
Enzymatic activity assays
To measure enzymatic activity of EXE on different
modified DNA substrates (25 nM), each reaction was pre-
pared following different concentration of the extract,J. Biol. Chem. (2021) 296 100569 13
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Reactions were performed in a buffer containing 20 mM
Tris-HCl pH 7.4, 25 mM KCl, 4 mMMgCl2, 0.1% BSA, 0.01%
Tween20, for the indicated time at 37 C. To measure
enzymatic activity of EXE on modified RNA substrate
(250 nM), each reaction was prepared following different
concentrations of the extract in a buffer containing 10 mM
Tris-HCl pH 7.4, 25 mM KCl, 1 mM MgCl2, for the indicated
time at 37 C. Final volume for each reaction was 10 μl. At
the end of all reactions, samples were blocked with a stop
solution, containing 99.5% v/v Formamide (Sigma-Aldrich,
Milan, Italy), supplemented with 10X Orange Loading Dye
(LI-COR Biosciences, Milan, Italy) and heated at 95 C for
5 min. Then, all samples were loaded onto a 7 M denaturing
20% polyacrylamide gel in TBE buffer pH 8.0 and run at 4 C
at 300V for 1 h. Then, the non-incised substrate (S) and the
incision product (P) bands were quantified using Image
Studio software (LI-COR GmbH, Germany).
Statistical analysis
Statistical analyses were performed by using the Student’s t-
test in GraphPad Prism software. When p < 0.05, data were
considered as statistically significant.
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